{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Exact logistic modeling investigation would yield a point and 90% CI estimate of the odds ratio for response.","groups":[{"description":"Patients receive vorinostat PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nVorinostat: Given PO","id":"OG000","title":"Treatment (Vorinostat)"}],"populationDescription":"HR23B was not measured in any participant.","reportingStatus":"POSTED","timeFrame":"Up to 180 days after the last dose of vorinostat maximum treatment duration= 24 months","title":"Expression Level of HR23B","type":"OTHER_PRE_SPECIFIED"}